Integrated Systemic Analysis of FAM72A to Identify Its Clinical Relevance, Biological Function, and Relationship to Drug Sensitivity in Hepatocellular Carcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 9

PMID 36483027

Authors

Qi Zhou

Lingjun Chen

Luo Yang

Haoxiong Zhou

Yan Chen

Yunwei Guo

Affiliations

Soon will be listed here.

Abstract

Background: The family with sequence similarity 72 member A (FAM72A) protein has been identified as an effector of multiple pathological processes in many cancers. The value of FAM72A in HCC remains largely unknown.

Methods: Data from TCGA-LIHC, ICGC-LIRI-JP, IMvigor210, cBioPortal, GeneMANIA, and TIMER were processed and visualized to explore the association between FAM72A and the prognosis, stemness phenotype, mutational burden, immune cell infiltration, and drug sensitivity in HCC patients. Potential pathways were also revealed. Furthermore, we experimentally verified the results and using immunohistochemistry, western blotting, and CCK-8 assays.

Results: First, FAM72A mRNA expression was significantly upregulated in HCC. High FAM72A expression was independently associated with a poor prognosis. Experimental validation confirmed that FAM72A was remarkably overexpressed in HCC patients and mice. Moreover, FAM72A knockdown suppressed HCC cell proliferation. In addition, the frequency of TP53 mutations was significantly higher in the high FAM72A expression group. Subsequently, the enrichment analysis revealed that FAM72A was closely related to immune processes and mTOR pathways. Silencing FAM72A increased the expression levels of mTOR in HCC cell lines. The FAM72A-mTOR pathway was strongly associated with a poor prognosis for patients with HCC. Patients with high FAM72A expression levels might be more resistant to sorafenib. Furthermore, the expression of FAM72A and mTOR was significantly associated with the abundance of some tumor-infiltrating immune cells, especially CD4 T cells. Finally, patients with high levels of FAM72A and mTOR were more sensitive to immunotherapy.

Conclusions: FAM72A, a member of the FAM72 family, might be a prognostic and immunotherapeutic target for HCC patients.

Citing Articles

Prognostic and Immunological Implications of FAM72A in Pan-Cancer and Functional Validations.

Bai Y, Cao K, Zhang P, Ma J, Zhu J Int J Mol Sci. 2023; 24(1).

PMID: 36613817 PMC: 9820597. DOI: 10.3390/ijms24010375.

References

Kutzner A, Pramanik S, Kim P, Heese K . All-or-(N)One - an epistemological characterization of the human tumorigenic neuronal paralogous FAM72 gene loci. Genomics. 2015; 106(5):278-85. DOI: 10.1016/j.ygeno.2015.07.003. View

Guo C, Zhang X, Fink S, Platzer P, Wilson K, Willson J . Ugene, a newly identified protein that is commonly overexpressed in cancer and binds uracil DNA glycosylase. Cancer Res. 2008; 68(15):6118-26. PMC: 2614906. DOI: 10.1158/0008-5472.CAN-08-1259. View

Bhattacharya B, Miura T, Brandenberger R, Mejido J, Luo Y, Yang A . Gene expression in human embryonic stem cell lines: unique molecular signature. Blood. 2004; 103(8):2956-64. DOI: 10.1182/blood-2003-09-3314. View

Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B . Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007; 132(7):2328-39. DOI: 10.1053/j.gastro.2007.03.102. View

Jemal A, Ward E, Johnson C, Cronin K, Ma J, Ryerson B . Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst. 2017; 109(9). PMC: 5409140. DOI: 10.1093/jnci/djx030. View

Wang P, Hu Z, Zhou S, Yu S, Mao L, Su S . The spatial distribution of immune cell subpopulations in hepatocellular carcinoma. Cancer Sci. 2021; 113(2):423-431. PMC: 8819352. DOI: 10.1111/cas.15202. View

Ho N, Kutzner A, Heese K . Brain plasticity, cognitive functions and neural stem cells: a pivotal role for the brain-specific neural master gene |-SRGAP2-FAM72-|. Biol Chem. 2017; 399(1):55-61. DOI: 10.1515/hsz-2017-0190. View

Nehar S, Mishra M, Heese K . Identification and characterisation of the novel amyloid-beta peptide-induced protein p17. FEBS Lett. 2009; 583(19):3247-53. DOI: 10.1016/j.febslet.2009.09.018. View

Tan X, Xiong B, Zhang Y, Wang S, Zuo Q, Li J . FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma. Eur J Pharmacol. 2022; 931:175186. DOI: 10.1016/j.ejphar.2022.175186. View

10.

Karpisheh V, Ahmadi M, Abbaszadeh-Goudarzi K, Mohammadpour Saray M, Barshidi A, Mohammadi H . The role of Th17 cells in the pathogenesis and treatment of breast cancer. Cancer Cell Int. 2022; 22(1):108. PMC: 8897940. DOI: 10.1186/s12935-022-02528-8. View

11.

Wang L, Lin C, Chai C, Liu K, Chen J, Hsu S . Functional interaction of Ugene and EBV infection mediates tumorigenic effects. Oncogene. 2011; 30(26):2921-32. DOI: 10.1038/onc.2011.16. View

12.

Newell P, Toffanin S, Villanueva A, Chiang D, Minguez B, Cabellos L . Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009; 51(4):725-33. PMC: 2970800. DOI: 10.1016/j.jhep.2009.03.028. View

13.

Rahane C, Kutzner A, Heese K . Establishing a human adrenocortical carcinoma (ACC)-specific gene mutation signature. Cancer Genet. 2018; 230:1-12. DOI: 10.1016/j.cancergen.2018.10.005. View

14.

Trehanpati N, Vyas A . Immune Regulation by T Regulatory Cells in Hepatitis B Virus-Related Inflammation and Cancer. Scand J Immunol. 2017; 85(3):175-181. DOI: 10.1111/sji.12524. View

15.

Roybal K, Williams J, Morsut L, Rupp L, Kolinko I, Choe J . Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016; 167(2):419-432.e16. PMC: 5072533. DOI: 10.1016/j.cell.2016.09.011. View

16.

Long J, Wang A, Bai Y, Lin J, Yang X, Wang D . Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019; 42:363-374. PMC: 6491941. DOI: 10.1016/j.ebiom.2019.03.022. View

17.

Rahane C, Kutzner A, Heese K . A cancer tissue-specific FAM72 expression profile defines a novel glioblastoma multiform (GBM) gene-mutation signature. J Neurooncol. 2018; 141(1):57-70. DOI: 10.1007/s11060-018-03029-3. View

18.

Zhang T, Nie Y, Gu J, Cai K, Chen X, Li H . Identification of Mitochondrial-Related Prognostic Biomarkers Associated With Primary Bile Acid Biosynthesis and Tumor Microenvironment of Hepatocellular Carcinoma. Front Oncol. 2021; 11:587479. PMC: 8047479. DOI: 10.3389/fonc.2021.587479. View

19.

Li A, Zhang R, Zhang Y, Liu X, Wang R, Liu J . BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway. Am J Transl Res. 2019; 11(9):5573-5585. PMC: 6789287. View

20.

Rogier M, Moritz J, Robert I, Lescale C, Heyer V, Abello A . Fam72a enforces error-prone DNA repair during antibody diversification. Nature. 2021; 600(7888):329-333. DOI: 10.1038/s41586-021-04093-y. View